Check. Change. Control. Cholesterol™ Recognition Program - Data Collection Worksheet

The following data are needed for each healthcare organization seeking recognition by the Check.Change.Control. Cholesterol Program. This worksheet can be used to prepare for the formal data submission process, which begins February 5th. The **deadline to submit data is June 1, 2018**.

You will need basic practice contact information and the following information to complete the registration and data entry process. All information is for the calendar year of 2017.

**REGISTRATION**

| Q1) | What is the total adult (21-75 years) population for the healthcare organization? | Required Field |
| Q2) | What % of your patients are a race/ethnicity other than white, non-Hispanic? | Required Field/Estimation |
| Q3) | How many providers are in the health system? *(including all Physicians, NP, and PA)* | Required Field |
| Q4) | What Electronic Health Record system does your organization use? | Required Field |

**PARTICIPATION AWARD**

| Q5) | Does your organization currently calculate ASCVD Risk in your EHR? If yes, where? |
| | ☐ **Yes**, we currently calculate ASCVD Risk Estimations in our EHR. |
| | ☐ **Yes**, we rely on clinicians to calculate ASCVD Risk Estimations external to our EHR (our EHR does not have this functionality). |
| | ☐ **No**, we do not calculate or document ASCVD Risk Estimations at this time. |

| Q6) | Does your organization document the ASCVD Risk score in the EHR? If yes, where is the ASCVD risk score documented? |
| | ☐ **Yes**, we currently collect the results of ASCVD Risk Estimations in a discrete field in our EHR |
| | ☐ **Yes**, we rely on clinicians to calculate ASCVD Risk Estimations external to our EHR (our EHR does not have this functionality). |
| | ☐ **No**, we do not calculate or document ASCVD Risk Estimations at this time. |

| Q7) | My organization will commit to incorporate the ASCVD risk calculator into our practice. |
| | ☐ **Yes** ☐ **No** |
**GOLD AWARD:** MIPS #438 N/D

**Q8) Denominator:**
How many patients are in these risk groups? (total)  

- Adults aged ≥ 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD)

- OR-

- Adults aged ≥ 21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia

- OR-

- Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL

**Q9) Numerator:**
How many of these patients were prescribed, or were on, statins.

*Required Field*
MIPS #438

DESCRIPTION
Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the performance period:

- Adults aged ≥ 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD)
- Adults aged ≥ 21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia
- Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL

INSTRUCTIONS
This measure is to be submitted once per performance period for patients seen during the performance period. This measure may be submitted by eligible clinicians who provide the services in the measure-specific denominator coding.

DENOMINATOR
The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure.

THERE ARE THREE SUBMISSION CRITERIA FOR THIS MEASURE**:
1) Patients aged ≥ 21 years at the beginning of the measurement period with clinical ASCVD diagnosis
   - OR-
2) Patients aged ≥ 21 years at the beginning of the measurement period who have ever had a fasting or direct laboratory result of LDL-C ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia
   - OR-
3) Patients aged 40 to 75 years at the beginning of the measurement period with Type 1 or Type 2 diabetes and with an LDL-C result of 70–189 mg/dL recorded as the highest fasting or direct laboratory test result in the measurement year or during the two years prior to the beginning of the measurement period

**All patients who meet one or more of the following criteria indicated above would be considered at high risk for cardiovascular events under the ACC/AHA guidelines. When submitting this measure, determine if the patient meets denominator eligibility in order of each risk category.

NUMERATOR
Patients who are actively using or who receive an order (prescription) for statin therapy at any point during the measurement period

DEFINITIONS:
- **Statin therapy** - Administration of one or more of a group of medications that are used to lower plasma lipoprotein levels in the treatment of hyperlipoproteinemia.